Primary Tests for Kidney Monitoring
Doctors monitor kidney function during methotrexate therapy mainly through blood tests that measure serum creatinine levels and calculate the estimated glomerular filtration rate (eGFR). Creatinine clearance is checked before starting treatment and regularly afterward—often weekly during high-dose regimens or monthly for low-dose use—to detect early declines in kidney function. Methotrexate clearance depends on renal excretion, so impaired function raises toxicity risks like mucositis or bone marrow suppression.
Why Kidneys Matter for Methotrexate
Methotrexate is primarily eliminated by the kidneys (up to 90% unchanged in urine), making dose adjustments essential if eGFR falls below 60 mL/min. Elevated creatinine signals potential accumulation, prompting leucovorin rescue or dose holds. Hydration and urine alkalinization (e.g., with sodium bicarbonate) are standard to prevent crystal formation in renal tubules during high-dose therapy.
Frequency and Timing of Checks
- High-dose IV (e.g., cancer treatment): Baseline, daily during infusion, then every 24-48 hours until levels drop below 0.1 micromolar.
- Low-dose oral (e.g., rheumatoid arthritis): Baseline, then every 1-3 months, or more often if risk factors like age >65, diabetes, or NSAIDs use.
Therapeutic drug monitoring via plasma methotrexate levels guides timing, especially if levels stay high >24 hours post-dose.
What Happens if Kidney Function Declines
If creatinine rises >50% above baseline or eGFR drops significantly, therapy pauses, fluids increase, and glucarpidase may be used for severe cases. NSAIDs, proton pump inhibitors, or other nephrotoxins are avoided to prevent additive damage. Patients with baseline CKD often need dose reductions (e.g., 50% if eGFR 30-60 mL/min).
Alternatives and Additional Monitoring
Urine output tracking and electrolytes (e.g., BUN, potassium) supplement blood tests. Cystatin C offers a more accurate eGFR in some cases over creatinine, especially with muscle-wasting conditions. For long-term users, annual imaging rules out obstruction.
[1] American College of Rheumatology Guidelines for Methotrexate in RA
[2] NCCN Guidelines for Acute Lymphoblastic Leukemia (high-dose MTX monitoring)
[3] UpToDate: Methotrexate nephrotoxicity and monitoring